Back to Stakeholders

Care Delivery & Psychedelic FacilitationClinical Care Delivery OrganizationsHealth Systems & Hospitals

Research, Drug Development & ManufacturingAcademic & Non-Profit ResearchIndependent Academic Research Groups

Care Delivery & Psychedelic FacilitationClinical Care Delivery Organizations

Care Delivery & Psychedelic Facilitation

Research, Drug Development & ManufacturingAcademic & Non-Profit Research

Research, Drug Development & Manufacturing

Mayo Clinic

United States

8 Trials1 Paper

Multi-campus academic medical center and one of the most recognized healthcare institutions in the world. Mayo Clinic researchers have published evidence reviews on psilocybin-assisted therapy for depression, anxiety, and alcohol use disorder, and have collaborated on ketamine clinical trials — including a biomarker study with the University of Michigan — for treatment-resistant depression.

Academic Research

1 papers

Published Papers

1

Trial Involvement

8

Distinct Focus Topics

0

Latest Publication

Feb 7, 2026

Recent Papers

Oral Ketamine for Chronic Pain: Towards an Evidence-Based Dosing Regimen

Journal of Pain Research - Feb 7, 2026

Quick Facts

Type: Other
HQ: United States
Website: Visit

Sponsored Trials

7

Intravenous Ketamine for Treatment-Resistant Depression (G2K)

Start Date: March 1, 2025
Compounds: Ketamine, Placebo

A Study of Ketamine Infusions to Treat Clinically-depressed ICU Patients

Start Date: December 1, 2023
Compounds: Ketamine, Placebo

Active not recruitingI

Ketamine Associated ACC GABA and Glutamate Change and Depression Remission

Start Date: March 1, 2019
Compounds: Ketamine

The BIO-K Study: A Single-Arm, Open-Label, Biomarker Development Clinical Trial of Ketamine for Non-Psychotic Unipolar Major Depression and Bipolar I or II Depression.

Start Date: January 6, 2017
Compounds: Ketamine

Ketamine for Depression and Suicide Risk

Start Date: January 9, 2014
Compounds: Ketamine

Oral Ketamine in the Treatment of Depression and Anxiety in Patients With Cancer

Start Date: January 8, 2012
Compounds: Ketamine, Placebo

Ketamine Anesthesia in Electroconvulsive Therapy

Start Date: January 5, 2011
Compounds: Ketamine, Placebo

Collaborated Trials

1

Efficacy of Repeated Ketamine Infusions for Treatment-resistant Depression

Start Date: April 1, 2015
Compounds: Ketamine, Placebo

Research Papers

1

Open Accessmeta

Oral Ketamine for Chronic Pain: Towards an Evidence-Based Dosing Regimen

This systematic review (s=27) of oral ketamine for chronic cancer and non-cancer pain found that mean pain scores fell from 7.72/10 to 3.2/10 over 30 to 90 days, though only 5 studies had sufficient dosing consistency for quantitative analysis, with 35 mg/70kg three times daily identified as an effective regimen with an acceptable safety profile.

Published: February 7, 2026
Journal: Journal of Pain Research
Authors: Winegarden, J., Brose, A., Storm, A., Mortensen, A., Carr, D.